Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to $7.5 million.

  • Whitehawk Therapeutics' Gains from Investment Securities changed N/A to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 301259.88%. This contributed to the annual value of -$518000.0 for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Whitehawk Therapeutics' Gains from Investment Securities stood at $7.5 million.
  • Over the past 5 years, Whitehawk Therapeutics' Gains from Investment Securities peaked at $7.5 million during Q3 2025, and registered a low of -$159000.0 during Q2 2023.
  • In the last 5 years, Whitehawk Therapeutics' Gains from Investment Securities had a median value of -$114000.0 in 2025 and averaged $1.2 million.
  • In the last 5 years, Whitehawk Therapeutics' Gains from Investment Securities surged by 234385.76% in 2021 and then crashed by 48709.68% in 2023.
  • Over the past 5 years, Whitehawk Therapeutics' Gains from Investment Securities (Quarter) stood at $1.3 million in 2021, then tumbled by 97.61% to $31000.0 in 2022, then tumbled by 487.1% to -$120000.0 in 2023, then decreased by 25.83% to -$151000.0 in 2024, then skyrocketed by 5076.49% to $7.5 million in 2025.
  • Its Gains from Investment Securities was $7.5 million in Q3 2025, compared to -$114000.0 in Q1 2025 and -$151000.0 in Q4 2024.